For more than 20 years, Roche and Genentech have helped lay the scientific groundwork for personalized healthcare with treatments that target the underlying biology of cancer and other diseases.
Now we are working on taking personalized healthcare toward a future in which treatments are targeted to an individual’s needs and unique genetic profile. Our personalized healthcare partnering strategy is built around identifying strategic partners with whom we can pursue this vision. With Flatiron and Foundation Medicine as part of the Roche Group we are shaping new ways of realizing the promise of personalized healthcare.
Foundation Medicine (FMI) – Roche Group acquisition to further develop FMI's comprehensive genomic profiling platform and support the Roche Group’s PHC strategy
Flatiron – Roche Group acquisition to advance use of real-world evidence in regulatory decision-making and at point of care
Gregg Talbert, Head of Digital & Personalized Healthcare, Pharma Partnering
Erika Pollex, Search & Evaluation Lead Digital & Personalized Healthcare, Pharma Partnering